| Dermatitis |
| Completed | 3b | 485 | Europe, Canada, US, RoW | Upadacitinib, ABT-494, RINVOQ | AbbVie, AbbVie Inc. | Atopic Dermatitis | 09/23 | 09/23 | | |
2020-004194-51: A clinical trial evaluating the efficacy and safety of the drugs - cyclosporine and methotrexate in children and adolescents with moderate to severe atopic dermatitis. Badanie kliniczne oceniające skuteczność i bezpieczeństwo stosowania leków - cyklosporyny i metotreksatu u dzieci i młodzieży z atopowym zapaleniem skóry o nasileniu umiarkowanym do ciężkiego. |
|
|
| Not yet recruiting | 3 | 317 | Europe | Cyclosporin, Methotrexate, Mometasone furoate, Tacrolimus, Oral solution, Ointment | Medical University of Lodz, Medical Research Agency | Atopic dermatitis Atopowe Zapalenie Skóry, Atopic dermatitis Atopowe Zapalenie Skóry, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2022-002644-48: Clinical study to compare two cutaneous creams with the active substance methylprednisolone aceponate 0.1% and one cutaneous cream without active substance for patients with atopic dermatitis. |
|
|
| Not yet recruiting | 3 | 330 | Europe | Advantan 0.1% Creme, Methylprednisolone Aceponate 0.1% Cream, D07AC14, Cream, Advantan 0,1% Creme | Dermapharm AG, Dermapharm AG | Atopic dermatitis, Atopic dermatitis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2004-003901-25: A multi-centre, double-blind, vehicle-controlled, randomised group comparative trial to evaluate the efficacy, steroid sparing properties, safety and acceptability of a topically applied sodium cromoglicate lotion (Altoderm®) in the treatment of atopic dermatitis in children. |
|
|
| Ongoing | 3 | 174 | Europe | Altoderm, Cream | Thornton & Ross Ltd | Atopic dermatitis | | | | |
2004-005085-21: Scalp lotion for the treatment of pityriasis capitis (severe dandruff) and seborrhoeic dermatitis. |
|
|
| Ongoing | 3 | 150 | Europe | Ketocol Lotion, Nizoral Shampoo, KCSA, | Dermal Laboratories Limited | Seborrhoeic dermatitis and pityriasis capitis of the scalp. | | | | |
2005-006208-21: Clinical Efficacy of Pimecrolimus Cream in Seborrheic Dermatitis. Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and differentiation in seborrheic dermatitis: a randomized, double-blind study in adults with seborrheic dermatitis treated with 1 % pimecrolimus cream versus 2 % ketoconazole cream as control. |
|
|
| Ongoing | 3 | 32 | Europe | elidel 1% cream, Nizoral 2% cream, elidel 1% cream, Nizoral 2% cream | Department of Dermatology, University of Kiel | Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and differentiation in seborrheic dermatitis | | | | |
2007-004649-14: Safety of ASF 1057 cream 0.5% under long term use in the treatment of seborrhoeic dermatitis: A 12 month open label extension multi-centre phase III trial |
|
|
| Ongoing | 3 | 150 | Europe | ASF-1057-Cream 0.5%, | Astion Pharma A/S | Seborrhoeic dermatitis | | | | |
2008-005469-67: A research study looking at a new lotion for the treatment of eczema in children. |
|
|
| Ongoing | 3 | 200 | Europe | Altoderm, | Thornton & Ross Limited, Thornton & Ross Ltd | Paediatric atopic dermatitis | | | | |
2009-011132-34: A 24 week multinational multi-center study consisting of a 12-week single blind study to evaluate the efficacy and safety of methotrexate versus Azathioprin treatment in adult patients with chronic severe atopic dermatitis (AD) and a 12-week follow up period. |
|
|
| Ongoing | 3 | 42 | Europe | Methotrexaat, Azathioprine, Methotrexaat 2,5 PCH, tabletten 2,5 mg, Azathioprine, Methotrexaat 2,5 PCH, tabletten 2,5 mg, Azathioprine | Academic Medical Center, Department of dermatology | Patients with severe atopic dermatitis, defined as a score of 8-9 on the Rajka and Langeland criteria who are unresponsive, intolerant or contra-indicated to cyclisporin treatment. | | | | |
2010-021568-14: Estudio clínico para evaluar la eficacia y tolerabilidad de Denutraxan® sobre el alivio del prurito asociado a dermatitis atópica en niños. |
|
|
| Ongoing | 3 | 30 | Europe | DENUTRAXAN 10 mg/ml Emulsión cutanea, DENUTRAXAN 10 mg/ml Emulsión cutanea | ISDIN, S.A. | Prurito | | | | |
2014-005593-11: Diacerein for the treatment of atopic dermatitis Diacerein zur Behandlung von atopischer Dermatitis |
|
|
| Ongoing | 3 | 10 | Europe | Diacerein, 13739-02-1, | University Hospital of Dermatology, Paracelsus Medical University, University Clinics for Dermatology, Salzburg | Atopic dermatitis Atopische Dermatitis | | | | |
BREEZE-AD4, NCT03428100 / 2017-004574-34: A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable |
|
|
| Completed | 3 | 463 | Europe, Japan, RoW | Baricitinib, LY3009104, Placebo, Topical corticosteroid | Eli Lilly and Company, Incyte Corporation | Atopic Dermatitis | 11/19 | 04/23 | | |
|
ChiCTR1800016644: Clinical study in treatment of asthma by acupoint sticking therapy based on Raman spectrum in monitoring of dermatitis degree |
|
|
| Not yet recruiting | 3 | 150 | | Placebo application ;Acupoint application | Jiangsu Province Hospital of Chinese Medicine; Jiangsu Province Hospital of Chinese Medicine, Key R & D Program (Social Development) of Jiangsu science and Technology Department | Asthma | | | | |
| Completed | 3 | 1645 | Europe, Japan, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company, Incyte Corporation | Atopic Dermatitis | 09/20 | 07/23 | | |
| Active, not recruiting | 3 | 912 | Europe, Canada, Japan, US, RoW | Placebo for Upadacitinib, Upadacitinib, ABT-494, RINVOQ™ | AbbVie | Atopic Dermatitis | 01/21 | 10/25 | | |
|
AD Up, NCT03568318 / 2017-005126-37: A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Enrolling by invitation | 3 | 1500 | Europe, Canada, Japan, US, RoW | Placebo, Upadacitinib, ABT-494, RINVOQ™, Topical corticosteroids (TCS) | AbbVie | Atopic Dermatitis | 02/21 | 11/30 | | |
| Active, not recruiting | 3 | 912 | Europe, Canada, US, RoW | Placebo for Upadacitinib, Upadacitinib, ABT-494, RINVOQ® | AbbVie | Atopic Dermatitis | 03/21 | 12/25 | | |
|
|
ACTRN12617001380381: The PEBBLES study – Testing a strategy for preventing eczema and food allergy in high risk infants |
|
|
| Active, not recruiting | 3 | 760 | | | University of Melbourne, National Health and Medical Research Council, Primus Pharmaceuticals | Eczema/Atopic Dermatitis, Food Allergy | | | | |
2020-005976-36: Trial to investigate which atopic dermatitis patients will respond to the biologic therapy tralokinumab |
|
|
| Not yet recruiting | 3 | 42 | Europe | Tralokinumab | Karolinska Universitetssjukhuset, Dermagnostix R&D | Atopic Dermatitis, Atopic Dermatitis, Diseases [C] - Immune System Diseases [C20] | | | | |
2019-002686-35: Clinical study to compare two cutaneous ointments with the active substance methylprednisolone aceponate 0.1% and one cutaneous ointment without active substance for patients with atopic dermatiits. |
|
|
| Ongoing | 3 | 330 | Europe | Advantan 0,1% Salbe, Methylprednisolone Aceponate 0.1%, D07AC14, Ointment, Advantan 0,1% Salbe | Dermapharm AG, Dermapharm AG | Atopic dermatitis, Atopic dermatitis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2019-001711-23: Evaluation of Cicaderma® ointment efficacy versus current practice of each participating center in patients presenting a non-metastatic breast cancer treated after surgery by radiotherapy Evaluation de l’efficacité de la pommade Cicaderma® versus la pratique courante de chaque centre chez des patientes atteintes d’un cancer du sein non métastatique traitées après chirurgie par radiothérapie |
|
|
| Not yet recruiting | 3 | 248 | Europe | Ointment, Cicaderma® | Centre Léon Bérard, Laboratoires BOIRON | Breast adenocarcinoma treated with post-operative radiotherapy Post-operative breast cancer radiotherapy Adénocarcinome du sein traité par radiothérapie postopératoire Radiothérapie postopératoire du cancer du sein, Breast cancer treated with post-operative radiotherapy Post-operative breast cancer radiotherapy Cancer du sein traité par radiothérapie postopératoire Radiothérapie postopératoire du cancer du sein, Diseases [C] - Cancer [C04] | | | | |
2019-004300-34: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB WHEN USED IN COMBINATION WITH TOPICAL CORTICOSTEROID TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS |
|
|
| Not yet recruiting | 3 | 225 | Europe | Lebrikizumab, DRM06, Solution for injection in pre-filled syringe | Dermira, Inc., Dermira, Inc. | Atopic dermatitis, Atopic dermatitis (AD) or eczema is a common inflammatory skin disease characterized by dry skin, red and crusting rash and intense pruritus (itch) that may affect people of all ages., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2021-002166-40: A Multicenter trial to Assess the Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Estudio multicéntrico para evaluar la seguridad y eficacia del Nemolizumab in pacientes con dermatitis atópica de moderada a severa. |
|
|
| Ongoing | 3 | 270 | Europe | Nemolizumab, CD14152, Powder and solution for solution for injection | Galderma S.A., Galderma S.A. | Moderate-to-Severe Atopic Dermatitis Dermatitis atópica de modera a severa, Moderate-to-Severe Atopic Dermatitis Dermatitis atópica de modera a severa, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT04678882: Dupilumab in Japanese Patients With Atopic Dermatitis |
|
|
| Completed | 3 | 62 | Japan | Placebo, Dupilumab SAR231893 | Sanofi, Regeneron Pharmaceuticals | Atopic Dermatitis | 12/21 | 10/23 | | |
NCT06361992: Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children |
|
|
| Completed | 3 | 58 | RoW | Blue Cap Foam | Catalysis SL | Atopic Dermatitis, Atopic Dermatitis and Related Conditions, Atopic Dermatitis Eczema, Atopic Dermatitis \(AD\) | 09/23 | 02/24 | | |
| Active, not recruiting | 3 | 516 | Europe, Japan, RoW | Baricitinib, LY3009104, Placebo, Topical corticosteroid | Eli Lilly and Company, Incyte Corporation | Atopic Dermatitis | 04/22 | 05/26 | | |
2019-004301-28: AN OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS |
|
|
| Not yet recruiting | 3 | 200 | Europe | Lebrikizumab, DRM06, Solution for injection in pre-filled syringe | Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company, Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company | Atopic dermatitis, Atopic dermatitis (AD) or eczema is a common inflammatory skin disease characterized by dry skin, red and crusting rash and intense pruritus (itch) that may affect people of all ages., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
ADhere-J, NCT04760314: A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Completed | 3 | 286 | Japan | Lebrikizumab, LY3650150, Placebo, Topical Corticosteroid | Eli Lilly and Company | Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases, Skin Diseases, Genetic | 07/22 | 02/23 | | |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
CICA-RT, NCT04300829: Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients |
|
|
| Recruiting | 3 | 248 | Europe | cicaderma + simple hygiene rules, Cicaderma ointment and simple hygiene rules, Simple hygiene rules and a maximum of one topical treatment | Centre Leon Berard | Breast Adenocarcinoma, Radiation Dermatitis, Radiation Toxicity | 09/22 | 10/22 | | |
| Recruiting | 3 | 366 | RoW | TD03, TD07, Ketoconazole 2% Shampoo | Sao Thai Duong Joint Stock Company, Big Leap Clinical Research Support Joint Stock Company | Scalp Dermatitis | 12/22 | 06/23 | | |
NCT05136261: Evaluating the Efficacy and Tolerability of Ceradan Advanced Cream in the Treatment of Children With Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 60 | NA | Ceradan ® Advanced Cream, Basic cream | KK Women's and Children's Hospital | Atopic Dermatitis Eczema | 12/22 | 12/22 | | |
NCT05372653: A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis |
|
|
| Completed | 3 | 41 | Japan | OPA-15406, difamilast | Otsuka Pharmaceutical Co., Ltd. | Atopic Dermatitis (AD) | 12/22 | 11/23 | | |
| Recruiting | 3 | 308 | RoW | FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL, Placebo | Kang Stem Biotech Co., Ltd. | Dermatitis, Atopic | 01/23 | 04/23 | | |
NCT05149313 / 2021-002967-23: A Study of Lebrikizumab in Combination With Topical Corticosteroids in Participants Having Atopic Dermatitis (AD) That Are Not Adequately Controlled or Non-eligible for Cyclosporine |
|
|
| Completed | 3 | 331 | Europe | Lebrikizumab, Lebrikizumab-matching Placebo | Almirall, S.A. | Dermatitis, Atopic, Eczema | 01/23 | 05/24 | | |
|
NCT05032859: Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102) |
|
|
| Completed | 3 | 406 | Canada, US | tapinarof cream, 1%, vehicle cream | Dermavant Sciences GmbH | Atopic Dermatitis | 02/23 | 02/23 | | |
NCT05014568: Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults |
|
|
| Completed | 3 | 407 | Canada, US | tapinarof cream, 1%, Vehicle cream | Dermavant Sciences GmbH | Atopic Dermatitis | 03/23 | 04/23 | | |
NCT05498467: The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis |
|
|
| Not yet recruiting | 3 | 20 | NA | Anakinra, Sodium Chloride 9mg/ml Injection | Herlev and Gentofte Hospital | Allergic Contact Dermatitis | 04/23 | 08/23 | | |
NCT04921969: A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) |
|
|
| Completed | 3 | 330 | Canada, US | Ruxolitinib, Jakafi, Vehicle Cream, Placebo | Incyte Corporation | Atopic Dermatitis | 05/23 | 04/24 | | |
2021-005382-40: A new medication (capsules) for treatment of Rosacea (a type of skin inflammation) |
|
|
| Not yet recruiting | 3 | 320 | Europe | DFD-29, Capsule | Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories Ltd., Journey Medical Corporation | Rosacea, Rosacea is a common skin condition that causes blushing or flushing and visible blood vessels in the face. It may also produce small, pus-filled bumps., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT04283968: Efficacy of Fecal Microbial Transplantation Treatment in Adults With Atopic Dermatitis |
|
|
| Recruiting | 3 | 50 | RoW | Fecal Microbial Transplantation, placebo fecal transplantation | Tel-Aviv Sourasky Medical Center, Weizmann Institute of Science | Atopic Dermatitis | 06/23 | 06/24 | | |
| Completed | 3 | 652 | Canada, US | ARQ-151 Active, ARQ-151 Vehicle | Arcutis Biotherapeutics, Inc. | Atopic Dermatitis Eczema | 06/23 | 06/23 | | |
|
NCT05326672: Phase III Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Atopic Dermatitis |
|
|
| Recruiting | 3 | 240 | RoW | Benvitimod Cream, Placebo | Peking University People's Hospital, Zhonghao Pharmaceutical | Atopic Dermatitis | 06/23 | 12/23 | | |
INJECZTRA, NCT05194540: Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 136 | US | Tralokinumab | LEO Pharma | Atopic Dermatitis | 06/23 | 06/23 | | |
NCT05375929: A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India |
|
|
| Active, not recruiting | 3 | 189 | RoW | Abrocitinib 100 mg, Abrocitinib 200 mg | Pfizer | Atopic Dermatitis | 06/23 | 03/24 | | |
NCT05608343: This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD) |
|
|
| Completed | 3 | 153 | US | Difamilast, Placebo | Acrotech Biopharma Inc. | Atopic Dermatitis | 10/23 | 10/23 | | |
NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab |
|
|
| Active, not recruiting | 3 | 120 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 01/24 | 12/24 | | |
COAST 1, NCT06130566: A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 420 | Europe, Canada, US, RoW | Amlitelimab, SAR445229, Placebo | Sanofi | Dermatitis Atopic | 09/25 | 12/25 | | |
| Recruiting | 3 | 360 | Europe | SanaCutan Basiscreme | Infectopharm Arzneimittel GmbH, Gesellschaft für Therapieforschung mbH | Atopic Dermatitis, Infant, Newborn | 12/23 | 06/24 | | |
NCT05676242: A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 400 | RoW | Jaktinib Hydrochloride Tablet | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 12/24 | 12/24 | | |
NCT06181435: A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) |
|
|
| Recruiting | 3 | 420 | Europe, Japan, US, RoW | Amlitelimab, SAR445229, Placebo | Sanofi | Dermatitis Atopic | 10/25 | 02/26 | | |
NCT05667623: To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD |
|
|
| Recruiting | 3 | 270 | RoW | 1% OPA-15406 Ointment, 0% OPA-15406 Vehicle | Otsuka Beijing Research Institute | Atopic Dermatitis (AD) | 07/24 | 01/25 | | |
NCT05650320: To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD |
|
|
| Recruiting | 3 | 240 | RoW | 0.3% OPA-15406 Ointment, 1% OPA-15406 Ointment, 0% OPA-15406 vehicle | Otsuka Beijing Research Institute | Atopic Dermatitis (AD) | 11/24 | 05/25 | | |
| Completed | 3 | 232 | Europe | Placebo pills of Radium bromatum, Radium bromatum placebo, Radium bromatum pills, Radium bromatum, Radium bromatum/Apis mellifica/Belladonna placebo pills, Radium bromatum/Apis mellifica/Belladonna placebo, Radium bromatum/Apis mellifica/Belladonna pills, Radium bromatum/Apis mellifica/Belladonna | Centre Hospitalier Universitaire de Saint Etienne, Institut de Cancérologie de la Loire | Breast Cancer | 01/24 | 04/24 | | |
ChiCTR2200059419: Phase III Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 240 | | Benvitimod Cream ;Placebo | Peking University People's Hospital; Guangdong Zhonghao Pharmaceutical Co., Ltd., Guangdong Zhonghao Pharmaceutical Co., Ltd. | Atopic Dermatitis | | | | |
NCT06216392: Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 450 | RoW | GR1802 injection, placebo | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Atopic Dermatitis | 06/25 | 01/26 | | |
SHORE, NCT06224348: A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids |
|
|
| Recruiting | 3 | 496 | Europe, Canada, Japan, US, RoW | Amlitelimab, SAR445229, Placebo, Topical corticosteroids, Topical calcineurin inhibitors | Sanofi | Dermatitis Atopic | 10/25 | 01/26 | | |
NCT06173284: Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 510 | RoW | 611, Matching placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic | 09/25 | 05/26 | | |
NCT06277245: A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis. |
|
|
| Recruiting | 3 | 354 | RoW | LNK01001, Placebo | Lynk Pharmaceuticals Co., Ltd | Atopic Dermatitis | 09/25 | 11/25 | | |
| Not yet recruiting | 3 | 75 | Japan | dupixent, Solution for injection in pre-filled syringe, dupixent | Sanofi K.K, Sanofi K.K | atopic dermatitis, atopic dermatitis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT06239311: Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. |
|
|
| Recruiting | 3 | 212 | Europe, RoW | Methotrexate, Placebo | medac GmbH | Moderate to Severe Atopic Dermatitis | 11/25 | 03/26 | | |
AQUA, NCT06241118: A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor |
|
|
| Recruiting | 3 | 249 | Europe, Canada, Japan, US, RoW | Amlitelimab, SAR445229, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus | Sanofi | Dermatitis Atopic | 03/26 | 06/26 | | |
NCT05571943: A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis |
|
|
| Active, not recruiting | 3 | 500 | US | Difamilast | Acrotech Biopharma Inc. | Atopic Dermatitis | 07/24 | 10/24 | | |
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color |
|
|
| Active, not recruiting | 3 | 80 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 05/24 | 12/24 | | |
NCT06224192: A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD |
|
|
| Recruiting | 3 | 100 | Canada, US | Rocatinlimab Prefilled Syringe, AMG 451 | Amgen | Atopic Dermatitis | 05/25 | 04/26 | | |
Level Up, NCT05601882 / 2022-002482-15: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Active, not recruiting | 3 | 880 | Europe, Canada, Japan, US, RoW | Upadacitinib, RINVOQ, Dupilumab | AbbVie, AbbVie Inc. | Atopic Dermatitis | 03/24 | 07/24 | | |
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 430 | RoW | Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid | Eli Lilly and Company | Atopic Dermatitis | 12/25 | 11/26 | | |
TRuE-AD4, NCT06238817: A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis |
|
|
| Recruiting | 3 | 225 | Europe, Canada, US, RoW | Ruxolitinib Cream, INCB018424 Phosphate Cream, Vehicle Cream | Incyte Corporation | Atopic Dermatitis | 08/25 | 10/25 | | |
NCT05456529: Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis |
|
|
| Active, not recruiting | 3 | 103 | Europe, Canada, US | Ruxolitinib Cream, INCB18424 cream | Incyte Corporation | Atopic Dermatitis (AD) | 04/24 | 04/24 | | |
NCT06383468: A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 420 | RoW | AK120 | Akeso | Atopic Dermatitis | 01/25 | 01/26 | | |
ESTUARY, NCT06407934: A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Monotherapy Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 961 | US | Amlitelimab, SAR445229, Placebo | Sanofi | Dermatitis Atopic | 06/26 | 01/27 | | |
Sleep Up, NCT06390722: A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 112 | NA | Upadacitinib, RINVOQ, Placebo for Upadacitinib | AbbVie | Atopic Dermatitis, Sleep Disturbance | 01/26 | 07/26 | | |
NCT06277765: Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis |
|
|
| Not yet recruiting | 3 | 180 | RoW | CM310, placebo | Keymed Biosciences Co.Ltd | Atopic Dermatitis | 05/25 | 05/25 | | |
NCT05526222: A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 438 | RoW | Jaktinib Hydrochloride Tablet | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 06/24 | 09/24 | | |
NCT06444165: Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 56 | US | Lebrikizumab Pen | Eli Lilly and Company | Atopic Dermatitis | 06/24 | 06/24 | | |
NCT06468956: Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 650 | RoW | SHR-1819, Placebo | Guangdong Hengrui Pharmaceutical Co., Ltd | Moderate to Severe Atopic Dermatitis | 04/25 | 03/26 | | |
TRAPEDS 2, NCT06311682: A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 195 | US | Tralokinumab + TCS, Placebo + TCS | LEO Pharma | Atopic Dermatitis | 03/26 | 04/28 | | |
Switch-Up, NCT06389136: A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab |
|
|
| Recruiting | 3 | 300 | US | Upadacitinib Dose A, ABT-494, RINVOQ, Dupilumab Dose A, Upadacitinib Dose B | AbbVie | Atopic Dermatitis | 08/25 | 03/26 | | |
| Active, not recruiting | 3 | 1672 | Europe, Canada, Japan, US, RoW | Tralokinumab | LEO Pharma | Atopic Dermatitis | 06/24 | 06/25 | | |
|
|
|
|
2024-000141-26: The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India. |
|
|
| Not yet recruiting | 3 | 200 | RoW | Abrocitinib, PF-04965842, Film-coated tablet, Cibinqo | Pfizer Inc., Pfizer Inc. | Moderate to severe atopic dermatitis, Atopic dermatitis is also known as atopic eczema. It is a type of inflammation of the skin that results in itchy, red, swollen, and cracked skin., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT05492721: Comparing Tissue Adhesives in Port Site Closure |
|
|
| Recruiting | 3 | 184 | US | 2-Octylcyanoacrylate, Dermabond, N-butyl-2-cyanoacrylate, Swiftset | The University of Texas Health Science Center, Houston | Dermatitis, Contact | 06/24 | 10/24 | | |
NCT05142774: Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis |
|
|
| Completed | 3 | 728 | Canada, US | Tapinarof cream, 1% | Dermavant Sciences, Inc. | Atopic Dermatitis | 02/24 | 03/24 | | |
| Active, not recruiting | 3 | 726 | Europe, Canada, Japan, US, RoW | Rocatinlimab, AMG 451, KHK 4083, Placebo | Amgen | Atopic Dermatitis | 07/24 | 08/24 | | |
|
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 300 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, DRM06, Placebo, Topical corticosteroid | Eli Lilly and Company, Dermira, Inc. | Atopic Dermatitis, Eczema | 07/24 | 06/25 | | |
Start Up, NCT06461897: A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 675 | NA | Upadacitinib, ABT-494, RINVOQ®, RINVOQ LQ, Dupilumab | AbbVie | Atopic Dermatitis | 08/27 | 06/30 | | |
NCT05265923: A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 500 | RoW | CM310, Placebo | Keymed Biosciences Co.Ltd | Atopic Dermatitis | 07/24 | 07/24 | | |
ROCKET-SHUTTLE, NCT05724199: A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) |
|
|
| Active, not recruiting | 3 | 746 | Europe, Canada, Japan, US, RoW | Rocatinlimab, AMG 451, Placebo | Amgen | Atopic Dermatitis | 09/24 | 01/25 | | |
| Active, not recruiting | 3 | 1188 | Europe, Canada, US, RoW | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company, Dermira, Inc. | Atopic Dermatitis | 09/24 | 04/25 | | |
| Completed | 3 | 1220 | Canada, US | ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% | Arcutis Biotherapeutics, Inc. | Atopic Dermatitis Eczema | 05/24 | 05/24 | | |
ROCKET-VOYAGER, NCT05899816: A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) |
|
|
| Active, not recruiting | 3 | 221 | Canada, US | Rocatinlimab, AMG 451, KHK4083, Placebo | Amgen | Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | 08/24 | 11/24 | | |
NCT06026891: Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis |
|
|
| Recruiting | 3 | 498 | RoW | MG-K10/Placebo | Shanghai Mabgeek Biotech.Co.Ltd | Atopic Dermatitis | 06/25 | 12/25 | | |
| Active, not recruiting | 3 | 769 | Europe, Canada, Japan, US, RoW | Rocatinlimab, AMG 451, Placebo | Amgen | Atopic Dermatitis | 01/25 | 03/25 | | |
KIND-1, NCT05387707: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis |
|
|
| Terminated | 3 | 287 | US | difelikefalin 0.25 mg, CR845, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream | Cara Therapeutics, Inc. | Pruritus, Atopic Dermatitis | 02/24 | 02/24 | | |
| Recruiting | 3 | 200 | US | Metal Panel T.R.U.E. Test | Allerderm | Atopic Dermatitis Eczema | 03/25 | 03/25 | | |
ADhope, NCT05990725: Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 240 | Europe | Lebrikizumab | Almirall, S.A. | Atopic Dermatitis, Eczema | 05/25 | 05/25 | | |
ROCKET-ASTRO, NCT05704738: A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) |
|
|
| Recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Rocatinlimab, AMG 451, Placebo | Amgen | Atopic Dermatitis | 09/25 | 12/25 | | |
ROCKET-Orbit, NCT05633355: A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) |
|
|
| Active, not recruiting | 3 | 187 | Europe, Canada, US, RoW | Rocatinlimab, AMG 451 | Amgen | Atopic Dermatitis | 05/25 | 07/25 | | |
NCT05455060: Effects of a Mixed Chinese Herbal Formula on Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 120 | NA | Chinese herbal formula (CHF), Placebo | Chang Gung Memorial Hospital, National Yang Ming University, Taipei Veterans General Hospital, Taiwan, Taipei Medical University | Atopic Dermatitis | 07/25 | 07/25 | | |
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, Placebo | Eli Lilly and Company | Atopic Dermatitis, Eczema | 06/26 | 06/26 | | |
NCT04989504: Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy |
|
|
| Active, not recruiting | 3 | 216 | US | Best Practice, Standard of Care, Wound Dressing Material, Quality-of-Life Assessment, Questionnaire Administration | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Breast Carcinoma, Mastectomy Patient | 12/25 | 12/25 | | |
